Analysis of Resistance Mmechanisms to Pralsetinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) from the ARROW Study

被引：0
|
作者：
Gainor, J. [1 ]
Curigliano, G. [2 ]
Doebele, R. C. [3 ]
Lin, J. J. [1 ]
Ou, S. -H. [4 ]
Miller, S. [5 ]
Turner, C. D. [5 ]
Subbiah, V. [6 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Univ Milan, European Inst Oncol, IRCCS, Milan, Italy
[3] Univ Colorado, Ctr Canc, Aurora, CO USA
[4] Univ Calif Irvine, Sch Med, Orange, CA 92668 USA
[5] Blueprint Medicines Corp, Cambridge, England
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA05.02
引用
收藏
页码：S5 / S5
页数：1
相关论文
共 50 条
  • [41] Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers
    Faraat Ali
    Kumari Neha
    Garima Chauhan
    [J]. Archives of Pharmacal Research, 2022, 45 (5) : 309 - 327
  • [42] Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers
    Ali, Faraat
    Neha, Kumari
    Chauhan, Garima
    [J]. ARCHIVES OF PHARMACAL RESEARCH, 2022, 45 (05) : 309 - 327
  • [43] Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial
    Subbiah, Vivek
    Cassier, Philippe A.
    Siena, Salvatore
    Garralda, Elena
    Paz-Ares, Luis
    Garrido, Pilar
    Nadal, Ernest
    Vuky, Jacqueline
    Lopes, Gilberto
    Kalemkerian, Gregory P.
    Bowles, Daniel W.
    Seetharam, Mahesh
    Chang, Jianhua
    Zhang, Hui
    Green, Jennifer
    Zalutskaya, Alena
    Schuler, Martin
    Fan, Yun
    Curigliano, Giuseppe
    [J]. NATURE MEDICINE, 2022, 28 (08) : 1640 - +
  • [44] Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: of response by line of therapy
    Liu, S. V.
    De Braud, F.
    Drilon, A.
    Doebele, R. C.
    Patel, M. R.
    Cho, B. C.
    Ahn, M-J.
    Chiu, C-H.
    Farago, A. F.
    Goto, K.
    Lee, J.
    Ohe, Y.
    Ou, S-H. I.
    Cassier, P.
    Tan, D. S. W.
    Otterson, G. A.
    Veronese, L.
    Osborne, S.
    Simmons, B.
    Siena, S.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S472 - S473
  • [45] Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.
    Subbiah, Vivek
    Cassier, Philippe A.
    Siena, Salvatore
    Alonso, Guzman
    Paz-Ares, Luis G.
    Garrido, Pilar
    Nadal, Ernest
    Curigliano, Giuseppe
    Vuky, Jacqueline
    Lopes, Gilberto
    Kalemkerian, Gregory Peter
    Bowles, Daniel W.
    Seetharam, Mahesh
    Chang, Jianhua
    Zhang, Hui
    Ye, Chaoyang
    Green, Jennifer
    Zalutskaya, Alena
    Schuler, Martin H.
    Fan, Yun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusion-positive advanced/metastatic NSCLC.
    Popat, Sanjay
    Felip, Enriqueta
    Kim, Edward S.
    de Marinis, Filippo
    Cho, Byoung Chul
    Wermke, Martin
    De langen, Adrianus
    Ferrara, Roberto
    Kanzler, Stephan
    Cecere, Fabiana Letizia
    Galetta, Domenico
    Lee, Dae Ho
    Gregorc, Vanesa
    Rodrigues, Ana
    Britschgi, Christian
    Rahman, Ahmadur
    Ndunda, Diana
    Noe, Johannes
    Lu, Danny
    Besse, Benjamin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Defining resistance mechanisms to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
    Tan, L.
    Solomon, B. J.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (12) : 1599 - 1600
  • [48] Updated overall efficacy and safety of selpercatinib in patients with RET fusion-positive non-small-cell lung cancer (NSCLC): LIBRETTO-001 study
    Besse, B.
    Drillon, A. E.
    Solomon, B. J.
    Subbiah, V.
    Tan, D. S. -W.
    Park, K.
    De Braud, F. G.
    Alonso, G.
    Wolf, J.
    Soldatenkova, V.
    Lin, A. K.
    French, P.
    Goto, K.
    Gautschi, O.
    [J]. SWISS MEDICAL WEEKLY, 2021, 151 : 34 - 34
  • [49] Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
    Ahn, M.
    Cho, B. C.
    Siena, S.
    Drilon, A.
    De Braud, F.
    Krebs, M.
    John, T.
    Karapetis, C.
    Johnson, A.
    Chow-Maneval, E.
    Multani, P.
    Doebele, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1783 - S1783
  • [50] Pralsetinib in acquired RET fusion-positive advanced non-small cell lung cancer patients after resistance to EGFR/ALK-TKI: A China multi-center, real-world data (RWD) analysis
    Hu, J.
    Tang, X.
    Guo, R.
    Wang, Y.
    Shen, H.
    Wang, H.
    Yao, Y.
    Cai, X.
    Yu, Z.
    Dong, G.
    Liang, F.
    Cao, J.
    Zeng, L.
    Su, M.
    Kong, W.
    Liu, L.
    Huang, W.
    Cai, C.
    Xie, Y.
    Mao, W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S62 - S62
12345